We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lpath CEO to Speak at Retinal Physician Symposium
Product News

Lpath CEO to Speak at Retinal Physician Symposium

Lpath CEO to Speak at Retinal Physician Symposium
Product News

Lpath CEO to Speak at Retinal Physician Symposium


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Lpath CEO to Speak at Retinal Physician Symposium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lpath, Inc., has announced that its CEO, Scott Pancoast, will be a panelist at the 7th Annual Retinal Physician Symposium on February 23, 2011 at the Palazzo Hotel in Las Vegas.

Focused on current and future treatment strategies in medical and surgical retina care, the symposium offers education, instruction, and insight on new therapies and treatments for posterior-segment disease and disorders, as well as valuable networking opportunities.

Following various presentations regarding early-stage development programs for ocular therapeutics, Pancoast will participate in a panel, moderated by Emmett Cunningham of Clarus Ventures, that will focus on the enormous opportunities that exist in the ophthalmology arena and how best to seize such opportunities.

Lpath will soon initiate two Phase II trials in the ophthalmology space with its promising drug candidate, iSONEP™: the PEDigree Study will evaluate the safety and efficacy of iSONEP in patients with RPE Detachment (PED), for which there is no approved drug, and the Nexus Study will evaluate the safety and efficacy in wet-AMD patients without PED.

Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.

Advertisement